NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-05-28

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019734

Locations: 🇺🇸
Surgery Branch, Bethesda, Maryland, United States

Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment

Phase 1

Completed

Conditions: Cancer
Prostate Cancer

Interventions: Procedure: Fiducial marker placement

First Posted Date: 2003-05-26

Last Posted Date: 2018-04-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00061347

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-05-26

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019175

Locations: 🇺🇸
Surgery Branch, Bethesda, Maryland, United States

Videoendoscopic Drainage of Infected Pancreatic Collections

Not Applicable

Completed

Conditions: Pancreatitis, Acute Necrotizing

Interventions: Procedure: Videoscopic-Assisted Retroperitoneal Debridement (VARD)

First Posted Date: 2003-05-23

Last Posted Date: 2018-09-11

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 40

Registration Number: NCT00061269

Locations: 🇺🇸
Veteran's Administration-Portland, Portland, Oregon, United States
🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸
Veteran's Administration Puget Sound, Seattle, Washington, United States

and more 3 locations

Thalidomide in Treating Patients With Myelofibrosis

Phase 2

Completed

Conditions: Primary Myelofibrosis

Interventions: Drug: thalidomide
Other: laboratory biomarker analysis

First Posted Date: 2003-05-23

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT00015821

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Obesity Prevention in African American School Children

Not Applicable

Completed

Conditions: Obesity

First Posted Date: 2003-05-23

Last Posted Date: 2010-01-13

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 900

Registration Number: NCT00061165

Locations: 🇺🇸
University of Illinois at Chicago, Department of Human Nutrition, Chicago, Illinois, United States

Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer

Phase 2

Completed

Conditions: Breast Cancer
Cervical Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer

First Posted Date: 2003-05-23

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019084

Locations: 🇺🇸
Medicine Branch, Bethesda, Maryland, United States

BMS-214662 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: BMS-214662
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-05-22

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00006242

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Not Applicable

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

Interventions: Biological: tyrosinase peptide
Biological: gp100 antigen
Biological: incomplete Freund's adjuvant
Other: laboratory biomarker analysis
Biological: sargramostim

First Posted Date: 2003-05-22

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00006243

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma

Phase 2

Completed

Conditions: Acute T-Cell Leukemia-Lymphoma

Interventions: Biological: Alemtuzumab

First Posted Date: 2003-05-21

Last Posted Date: 2012-10-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00061048

Locations: 🇺🇸
National Institutes of Health, National Cancer Institute, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy